𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis

✍ Scribed by Akiko Nishibu; Erika Sakai; Noritaka Oyama; Toshiyuki Yamamoto

Book ID
108929046
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
328 KB
Volume
53
Category
Article
ISSN
0004-8380

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Improvement of vascular endothelial func
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis
✍ P. P. Sfikakis; C. Papamichael; K. S. Stamatelopoulos; D. Tousoulis; K. G. Fragi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 102 KB πŸ‘ 2 views

## Abstract ## Objective Increased endothelin activity may play a role in the pathogenesis of vascular injury, a primary feature of systemic sclerosis (SSc; scleroderma). Our goal was to test the hypothesis that treatment with the oral endothelin receptor antagonist bosentan might improve vascular

Digital ulcers in systemic sclerosis: Pr
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
✍ J. H. Korn; M. Mayes; M. Matucci Cerinic; M. Rainisio; J. Pope; E. Hachulla; E. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 2 views

## Abstract ## Objective Recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis (SSc; scleroderma) and lead to pain, impaired function, and tissue loss. We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the